Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy.
BACKGROUND
Previously we reported a 2-month clinical trial of moxifloxacin therapy in eight patients with MB leprosy (7 LL and 1 BL), finding both rapid killing of M. leprae and clinical improvement, without serious side effects or toxicities. Here we report the outcomes in two patients treated with moxifloxacin.


METHODS
Two previously untreated LL patients were treated with a single 400 mg dose of moxifloxacin, no therapy for 7 days and then daily 400 mg moxifloxacin for 48 days. Clinical response, viability of M. leprae in the skin, and side effects/toxicities were carefully monitored.


RESULTS
In both patients a single dose of moxifloxacin resulted in significant killing of M. leprae (P < 0.001%). In both patients no viable M. leprae were found after 15 doses of moxifloxacin. Improvement in skin lesions occurred again remarkably rapidly and no untoward effects were noted.


CONCLUSIONS
Loss of viable M. leprae was quite rapid, similar to that found previously only for rifampicin, patients improved rapidly, and moxifloxacin was well tolerated.
Pardillo
Fe Eleanor F
FE
Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines.
Burgos
Jasmin
J
Fajardo
Tranquilino T
TT
Dela Crux
Eduardo
E
Abalos
Rodolfo M
RM
Paredes
Rose Maria D
RM
Andaya
Cora Evelyn S
CE
Gelber
Robert H
RH
D000328:Adult; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D050296:Microbial Viability / Q000187:drug effects*; D008875:Middle Aged; D000077266:Moxifloxacin; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000302:isolation & purification; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
D001372:Aza Compounds; D024841:Fluoroquinolones; D007917:Leprostatic Agents; D011804:Quinolines; D000077266:Moxifloxacin